October 25, 2017 07:05 AM EDTUpdated 07:59 AM

As National Party Congress concludes, China’s FDA seeks to write widely-anticipated drug reforms into law

Amber Tong

In a bid to move Chinese drug industry regulations closer to the US/European model, China’s FDA yesterday proposed significant changes to the nation’s Drug Administration …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

As National Party Congress concludes, China’s FDA seeks to write widely-anticipated drug reforms into law

Amber Tong

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Regeneron plans to buy 23andMe for $256M

David Liu, Sam Sternberg unveil new way to insert big genes in human cells

Prime Medicine sidelines only clinical program, replaces CEO and lays off some staff

Intellia's CRISPR therapy likely causes 'permanent' gene knockdown in ATTR amyloidosis

Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

As Na­tion­al Par­ty Con­gress con­cludes, Chi­na’s FDA seeks to write wide­ly-an­tic­i­pat­ed drug re­forms in­to law

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

As National Party Congress concludes, China’s FDA seeks to write widely-anticipated drug reforms into law